Pfizer protects $6.4bn heart disease blockbuster from generics, for now
Pfizer’s Vyndamax will be free from generics competition until 2031 in a boost to the company’s revenue streams.
Pfizer’s Vyndamax will be free from generics competition until 2031 in a boost to the company’s revenue streams.
Strong systems that enable trust and governance are key to enabling the growth of AI technologies in drug development.
The pharmaceutical industry continues to be a hotbed of patent innovation. Activity is driven by the evolution of treatment paradigms,...
Advancing pressure protection in biopharma: how integrated bypass technology elevates single-use pump design
CinnaGen Enters EU Market with EMA Approval for Zandoriah®
Eli Lilly and NVIDIA to build pharma’s “most powerful” supercomputer
Huawei’s three key steps to drive industrial intelligence forward and unleash AI’s full potential